Clinical Trials · NCT05950516
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Enrollment
- 478
- Start date
- Jul 2023
- Locations
- 1 site, China
- Primary endpoint
- Change in HbA1c